Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02210975
Other study ID # NL4834906814
Secondary ID
Status Recruiting
Phase N/A
First received August 4, 2014
Last updated August 6, 2014
Start date July 2014
Est. completion date February 2016

Study information

Verified date August 2014
Source Maastricht University Medical Center
Contact Nicolaas F Rinsma, MD
Phone +31433884190
Email n.rinsma@maastrichtuniversity.nl
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

Sleeve gastrectomy (SG) has gained popularity as both a staged and a definitive procedure for morbid obesity due to its technical simplicity, low-morbidity and excellent results both for weight loss and control of metabolic syndrome. There are however reports of SG worsening pre-existing GERD or causing new-onset GERD. Because of this, patients with pre-existing GERD have been denied the benefits of SG. In addition, patients that develop post-op GERD cannot undergo traditional anti-reflux surgery since the gastric fundus that is required for fundoplication is removed during the SG. Hence, patients with post-SG GERD not adequately controlled with medication can only opt for the more invasive gastric bypass procedure as their only surgical treatment option.

In a recently reported case study, an obese patient with severe GERD successfully treated with EndoStim underwent SG and maintained adequate GERD control with continued use of LES stimulation therapy. However electrical stimulation was not yet tested systematically in patients with prior gastric operation such as sleeve gastrectomy.

This study will test the hypothesis that electrical stimulation is effective in control of GERD associated with SG.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date February 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Subject is between 18 - 80 years of age.

2. Subject underwent a sleeve gastrectomy minimum one year prior to enrollment (in order to have reached a stable weight loss plateau).

3. Subject has a history of heartburn, regurgitation or both for >6 month prompting physician recommendation of continual daily use of PPI after sleeve gastrectomy.

4. Baseline off-PPI GERD-HRQL score = 20 following 10-14 days off PPI

5. Baseline off-PPI GERD-HRQLscore is at least 5 points higher than the on-PPI score or a positive relationship between the occurrence of their primary symptom during the pH impedance monitoring (symptom association probability = 95% or a SI score = 50%) is present.

6. Subject who are on standard medical therapy for 6 months or longer and experience discomfort or who are otherwise dissatisfied with GERD symptoms.

7. Subjects with a GERD condition that in the opinion of the PI justifies a minimally invasive reversible procedure prior to attempting a more drastic procedure such as a gastric bypass.

8. Subject has exhibited excessive lower esophageal acid exposure during 24-hour pH-metry of antisecretory therapy performed within 6 months of screening visit; pH < 4 for > 6% of total time.

9. Subject has a resting LES end expiratory pressure = 5mmHg on manometry performed within 6 months of enrollment.

10. Subject has no esophagitis or esophagitis = Grade C (LA classification) on upper endoscopy within 6 months of enrollment.

11. Subject has esophageal body contraction amplitude > 30 mmHg for >30% of swallows and > 30% peristaltic contractions on manometry.

12. Subject has signed the informed consent form and is able to adhere to study visit schedule.

Exclusion Criteria:

1. Subject has any non-GERD esophageal motility disorders.

2. Subject has evidence of obstruction or stricture in the gastric sleeve by a barium swallow and endoscopy.

3. Subject has any significant multisystem diseases.

4. Subject has an autoimmune or a connective tissue disorder (e.g. scleroderma, dematomyositis, Calcinosis-Raynaud's-Esophagus Sclerodactyly Syndrome (CREST), Sjogren's Syndrome, Sharp's Syndrome) requiring therapy in the preceding 2 years.

5. Subject has Barrett's epithelium (> M2; >C1) or any grade of dysplasia.

6. Subject has a hiatal hernia larger than 3 cm.

7. Subject has a body mass index (BMI) greater than 35 kg/m2.

8. Subject has Type 1 Diabetes Mellitus

9. Subject has uncontrolled Type 2 Diabetes Mellitus (T2DM) defined as HbA1c >9.5 in the previous 6 months, or has T2DM for > 10 years.

10. Subject has a history of suspected or confirmed esophageal or gastric cancer.

11. Subject has esophageal or gastric varices.

12. Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease.

13. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).

14. Subject requires chronic anticoagulant therapy.

15. Subject has dysphagia or esophageal peptic stricture, excluding Schatzki's ring.

16. Subject of child-bearing potential who is pregnant or intends to become pregnant during the trial period.

17. Subject is currently enrolled in other potentially confounding research.

18. History of any malignancy in the last 2 years.

19. Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.

20. Weight change of +/- 10% of the EWL (Excess Weight Loss) in the 3 months prior to enrollment.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
LES-Stimulation Device


Locations

Country Name City State
Netherlands Maastricht University Medical Center Maastricht

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center EndoStim Inc.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence and severity of any complications that are associated with the investigational stimulation device throughout the follow-up period. up to 12 month follow-up Yes
Primary Efficacy - Disease specific quality of life The change in patient's GERD-HRQL, where applicable, from baseline (as measured while off PPI) . Baseline, 6 and 12 month follow up No
Secondary pH-monitoring The change in baseline pH values of % 24-hour esophageal pH< 4.0 and number of reflux events >1minute and >5 minute duration with the same on-stimulation pH parameters at 6 months and at 12 months. Baseline, 6 and 12 month FU No
Secondary Questionnairres, symptom diary Change in symptoms frequency and severity at 6 months vs. baseline and at 12 months vs. baseline as measured by patient symptom diary, structured GI questionnaire, and patients quality of life measured by SF-12. baseline, 6 and 12 month FU No
Secondary Anti-secretory medication use Change in anti-secretory medication use as evaluated during the two weeks prior to the 6 mo and 12 mo follow up compared to baseline. Baseline, 6 and 12 month FU No
Secondary HR-manometry Change in LES end expiratory pressure (LESPpre) and the on-stimulation LES end expiratory pressure (LESPpost) at 6 months and 12 months in mmHg. Baseline, 6 and 12 month FU No
See also
  Status Clinical Trial Phase
Recruiting NCT06084572 - Prospective Evaluation of pH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus
Completed NCT03568825 - Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose N/A
Recruiting NCT04703374 - A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects Phase 1
Completed NCT04120025 - Effectiveness of Diaphragmatic Breathing on Reflux Symptoms in Outpatients N/A
Withdrawn NCT04771247 - Endoscopic Cardiac Band Ligation for the Management of Refractory GERD After Laparoscopic Sleeve Gastrectomy N/A
Completed NCT02575287 - Minimal Injuries From Esophagus Detected by Optical Enhancement Systemâ„¢ Associated to Optical Magnification HD Scopes N/A
Completed NCT01710800 - Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy N/A
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Completed NCT00287391 - Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Phase 4
Completed NCT00629564 - An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Phase 4
Completed NCT04243668 - ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA) N/A
Completed NCT03558477 - PK/PD Clinical Trial of YYD601 in Healthy Adult Male Phase 1
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Completed NCT05069493 - Long-term Follow-up After Hiatal Hernia Repair by Tension-free Mesh Closure or Simple Suturing
Terminated NCT04626232 - Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients N/A
Completed NCT03238534 - Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS Phase 4
Recruiting NCT05974722 - Mesh Vs Pledgets for Repair of Paraesophageal Hernia N/A
Recruiting NCT05781347 - Stretta Versus Conservative Treatment in Obese and Non-obese N/A
Completed NCT06141577 - A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects Phase 1
Recruiting NCT05108038 - A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects Phase 1